MATRIFEN transdermaalne plaaster Eesti - eesti - Ravimiamet

matrifen transdermaalne plaaster

takeda pharma as - fentanüül - transdermaalne plaaster - 12mcg 1h 10tk; 12mcg 1h 5tk; 12mcg 1h 16tk; 12mcg 1h 8tk; 12mcg 1h 2tk; 12mcg 1h 1tk; 12mcg 1h 20tk; 12mcg 1h 4tk

ALPRAZOLAM KRKA tablett Eesti - eesti - Ravimiamet

alprazolam krka tablett

krka d.d. novo mesto - alprasolaam - tablett - 1mg 20tk; 1mg 10tk; 1mg 50tk; 1mg 60tk; 1mg 100tk; 1mg 30tk

DIAZEPAM ACCORD tablett Eesti - eesti - Ravimiamet

diazepam accord tablett

accord healthcare b.v. - diasepaam - tablett - 5mg 25tk; 5mg 10tk; 5mg 28tk; 5mg 40tk; 5mg 30tk; 5mg 50tk; 5mg 100tk; 5mg 20tk

ALPRAZOLAM KRKA tablett Eesti - eesti - Ravimiamet

alprazolam krka tablett

krka d.d. novo mesto - alprasolaam - tablett - 0,25mg 20tk; 0,25mg 60tk; 0,25mg 10tk; 0,25mg 30tk; 0,25mg 100tk; 0,25mg 50tk

MATRIFEN transdermaalne plaaster Eesti - eesti - Ravimiamet

matrifen transdermaalne plaaster

takeda pharma as - fentanüül - transdermaalne plaaster - 75mcg 1h 20tk; 75mcg 1h 2tk; 75mcg 1h 4tk; 75mcg 1h 10tk; 75mcg 1h 5tk; 75mcg 1h 1tk; 75mcg 1h 3tk; 75mcg 1h 8tk

TRAVOPROST TEVA PHARMA silmatilgad, lahus Eesti - eesti - Ravimiamet

travoprost teva pharma silmatilgad, lahus

teva pharma b.v. - travoprost - silmatilgad, lahus - 40mcg 1ml 2.5ml 1tk; 40mcg 1ml 2.5ml 6tk

MATRIFEN transdermaalne plaaster Eesti - eesti - Ravimiamet

matrifen transdermaalne plaaster

takeda pharma as - fentanüül - transdermaalne plaaster - 50mcg 1h 8tk; 50mcg 1h 4tk; 50mcg 1h 2tk; 50mcg 1h 3tk; 50mcg 1h 5tk; 50mcg 1h 10tk; 50mcg 1h 16tk

ALPRAZOLAM KRKA tablett Eesti - eesti - Ravimiamet

alprazolam krka tablett

krka d.d. novo mesto - alprasolaam - tablett - 2mg 20tk; 2mg 100tk; 2mg 60tk; 2mg 30tk; 2mg 50tk

ALPRAZOLAM KRKA tablett Eesti - eesti - Ravimiamet

alprazolam krka tablett

krka d.d. novo mesto - alprasolaam - tablett - 0,5mg 10tk; 0,5mg 30tk; 0,5mg 60tk; 0,5mg 20tk

Tabrecta Euroopa Liit - eesti - EMA (European Medicines Agency)

tabrecta

novartis europharm limited  - capmatinib dihydrochloride monohydrate - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.